Cargando…

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

BACKGROUND: The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Nielsen, Torsten O., Eriksen, Jens Ole, Wehn, Pernille, Hood, Tressa, Ram, Namratha, Buckingham, Wesley, Ferree, Sean, Ejlertsen, Bent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062869/ https://www.ncbi.nlm.nih.gov/pubmed/30053900 http://dx.doi.org/10.1186/s13058-018-1012-0

Ejemplares similares

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
por: Skriver, Signe Korsgaard, et al.
Publicado: (2020)

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
por: Nielsen, Kåre, et al.
Publicado: (2023)

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015)

Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
por: Shenasa, Elahe, et al.
Publicado: (2022)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
por: Nielsen, Torsten, et al.
Publicado: (2014)

Danish Breast Cancer Cooperative Group
por: Christiansen, Peer, et al.
Publicado: (2016)

Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark
por: Hjorth, Cathrine Fonnesbech, et al.
Publicado: (2021)

Correction: Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark
por: Hjorth, Cathrine Fonnesbech, et al.
Publicado: (2023)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study
por: Cold, Søren, et al.
Publicado: (2022)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Statin use and risk of contralateral breast cancer: a nationwide cohort study
por: Langballe, Rikke, et al.
Publicado: (2018)

Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle
por: Yoshimura, Keiko, et al.
Publicado: (2014)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
por: Stovgaard, Elisabeth S, et al.
Publicado: (2021)

Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark
por: Hjorth, Cathrine F., et al.
Publicado: (2022)

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
por: Bruning, P. F., et al.
Publicado: (1990)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark
por: Collin, Lindsay J, et al.
Publicado: (2018)

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
por: Alvarado, Michael D., et al.
Publicado: (2015)

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna(®) Test in the management of early-stage breast cancers
por: Hequet, Delphine, et al.
Publicado: (2017)

Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
por: Larsen, Martin J., et al.
Publicado: (2013)

Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
por: Rossing, Maria, et al.
Publicado: (2021)

The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study
por: Bens, Annet, et al.
Publicado: (2020)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial
por: Møller, Tom, et al.
Publicado: (2020)

High Serum Estradiol Reduces Acute Hepatotoxicity Risk Induced by Epirubicin Plus Cyclophosphamide Chemotherapy in Premenopausal Women with Breast Cancer
por: Huang, Shunmin, et al.
Publicado: (2021)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
por: Bianco, A. R., et al.
Publicado: (1991)

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
por: Parisi, Francesca, et al.
Publicado: (2020)

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study
por: Lyng, Maria B., et al.
Publicado: (2012)

Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
por: Olafsdottir, Elinborg J., et al.
Publicado: (2020)

Premenopausal osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6hsdbfnbogb4revg2cfg70db8t